Steady progress over four decades toward understanding the pathogenesis and clinical
consequences of hepatic fibrosis has led to the expectation of effective antifibrotic drugs, yet …

Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only
in Western countries but also in Japan. Within the wide spectrum of NAFLD, nonalcoholic …

Despite tremendous research advancements in nonalcoholic fatty liver disease (NAFLD),
our understanding of sex differences in NAFLD remains insufficient. This review summarizes …

Over the past 2 decades, nonalcoholic fatty liver disease (NAFLD) has grown from a
relatively unknown disease to the most common cause of chronic liver disease in the world …

As the epidemics of obesity and type 2 diabetes mellitus increase worldwide, the prevalence
of non-alcoholic fatty liver disease (NAFLD) is increasing proportionately. The subtype of …

The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide. In
some patients with NAFLD, isolated steatosis can progress to advanced stages with non …

Objective Given significant advances in treatment of viral hepatitis and the growing epidemic
of obesity, the burden of the different types of liver diseases in the USA may be changing …

Background & Aims Although hepatitis B and C have been the main drivers of hepatocellular
carcinoma (HCC), nonalcoholic steatohepatitis (NASH) has recently become an important …

Once known exclusively for their role in nutrients absorption, primary bile acids,
chenodeoxycholic and cholic acid, and secondary bile acids, deoxycholic and lithocholic …

Non-alcoholic steatohepatitis (NASH) develops from non-alcoholic fatty liver disease
(NAFLD). Currently, around 25% of the population is estimated to have NAFLD, and 25% of …